Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
Yoshihisa Kobayashi(Harvard University), Pasi A. Jänne(Harvard University), Jamie L. Hutchins(Guardant (United States)), Magda Bahcall(Harvard University), Lesli A. Kiedrowski(Guardant (United States)), Fangxin Hong(Dana-Farber Cancer Institute), Prafulla C. Gokhale(Harvard University), Kristin S. Price(Guardant (United States)), Zihan Wei(The People's Hospital of Guangxi Zhuang Autonomous Region), Chhayheng Chhoeu(Boston University), Jiaqi Li(Dana-Farber Cancer Institute), Aaron Hardin(Guardant (United States))
Cited by 62
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k